Targeting Adaptive Stress and Innate Immunity

We have developed a differentiated pipeline of therapy candidates that address dynamic drivers of treatment resistance, cancer relapse and metastasis.  We are actively developing our therapeutic candidates in clinical trials for large indications of unmet need for patients.

Our Pipeline

Phase 1
Phase 2
Phase 3
Innate & Adaptive Immune Modulator
mBC Post HR Tx Failure
Odetiglucan + Pembrolizumab
Pancreatic Cancer
Liver Metastasis

Odetiglucan (Imprime PGG) is our systemically administered innate and adaptive immune modulator therapeutic candidate.   We are conducting a Phase 2 clinical trial of odetiglucan in combination with pembrolizumab in adults with metastatic, hormone-refractory breast cancer patients and plan to submit INDs for Phase 1b clinical trials in combination with a CD40 agonistic antibody in pancreatic cancer and as monotherapy in liver metastasis.

Adaptive Stress Modulators
Advanced RCC, Gastric Cancer & Other Advanced Solid Tumors
HC-5404 monoTx

HC-5404, our first adaptive stress product candidate, is a differentiated highly selective, orally bioavailable inhibitor of a key stress response protein kinase, PERK. We are developing HC-5404 for stress driven tumors, including von Hippel-Lindau, or VHL, mutated RCC, gastric cancer and other solid tumors.

Advanced HNSCC, CRC, Bladder Cancer & Other Advanced Solid Tumors
HC-7366 monoTx

HC-7366, our second adaptive stress product candidate, is a differentiated selective, orally bioavailable modulator of another key stress response protein kinase, GCN2.  We are developing HC-7366 for the treatment of advanced solid tumors and are exploring the potential of HC-7366 in hematological malignancies.

Targeting critical adaptive stress mitigating pathways

Modulating the immune system’s defense mechanisms